Antimicrobial And Opioid Stewardship - NAPLEX

1. A 38-year-old male (90 kg) is admitted for suspected meningitis and started empirically on ceftriaxone 2 g IV every 12 hours plus vancomycin IV plus ampicillin 2 g IV every 4 hours. Current meds: none. Labs: SCr 0.9 mg/dL; AST/ALT 20/19 units/L; WBC 18.0 $x10^3$/mcL. CSF culture grows Neisseria meningitidis susceptible to penicillin; blood cultures pending. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
   Answer: De-escalate to ceftriaxone monotherapy (or penicillin G if appropriate) and discontinue vancomycin and ampicillin based on culture results This question tests the antimicrobial stewardship principle of de-escalation, where empirical broad-spectrum antibiotics are narrowed based on culture and susceptibility results to minimize unnecessary exposure and resistance development. The key patient-specific factor is the CSF culture identifying Neisseria meningitidis susceptible to penicillin, with no evidence of Listeria or resistant organisms requiring broader coverage. De-escalating to ceftriaxone monotherapy (or penicillin G) and discontinuing vancomycin and ampicillin is the best choice as it targets the identified pathogen effectively while reducing the risks of toxicity and resistance associated with prolonged unnecessary antibiotics. Continuing triple therapy is incorrect because meningitis does not always require multiple antibiotics once the pathogen is identified and susceptible to narrower agents, and switching to oral amoxicillin/clavulanate is suboptimal as IV therapy is preferred for meningitis to ensure adequate CNS penetration. Adding metronidazole is unnecessary since N. meningitidis is not anaerobic and the regimen already covers typical meningitis pathogens. A key clinical pearl in stewardship is to always review culture results promptly to de-escalate therapy, ideally within 48-72 hours of initiation. Effective de-escalation frameworks involve assessing pathogen identification, susceptibility, and patient response to optimize outcomes and reduce adverse effects.
2. A 58-year-old female (70 kg) presents to the pharmacy for refill requests. She has chronic low back pain and has been taking oxycodone immediate-release 10 mg PO every 4 hours as needed (reports using 6 doses/day) for 8 months, plus cyclobenzaprine 10 mg PO at bedtime as needed and sertraline 100 mg PO daily. PDMP shows monthly fills from one prescriber; no benzodiazepines. Labs from last week: SCr 0.9 mg/dL; AST/ALT 28/31 units/L. Allergies: none. History includes depression and a hospitalization 3 months ago for constipation/ileus felt related to opioids. What is the pharmacist's best recommendation for opioid management?
   Answer: Recommend initiating a gradual taper (e.g., reduce total daily dose by about 10% per week or slower) with close follow-up and optimize nonopioid therapies This question evaluates opioid stewardship principles for managing long-term opioid therapy in chronic non-cancer pain, emphasizing risk assessment and tapering. The key patient-specific factor is the history of opioid-related constipation/ileus hospitalization and high daily opioid use (60 mg oxycodone equivalents) for over 8 months. Recommending a gradual taper (e.g., 10% per week) with nonopioid optimization is best as it mitigates withdrawal risks, addresses potential dependence, and aligns with CDC guidelines for high-risk patients. Continuing the current regimen ignores the recent adverse event and dependence risk, while abrupt discontinuation could precipitate severe withdrawal; increasing the dose would exacerbate constipation and overdose risk without improving function. A transferable clinical pearl is to use tools like the PDMP and risk assessments (e.g., ORT) to identify candidates for opioid tapering in chronic pain management. Always incorporate multimodal therapy, including nonopioids and behavioral interventions, to enhance safety and efficacy in opioid stewardship.
3. A 45-year-old female (60 kg) with cirrhosis (Child-Pugh C) is discharged after an ankle fracture repair and receives a prescription for oxycodone/acetaminophen 5 mg/325 mg: take 1–2 tablets PO every 4–6 hours as needed for pain. Current medications: lactulose 20 g PO three times daily, spironolactone 100 mg PO daily, furosemide 40 mg PO daily. Labs: AST/ALT 98/70 units/L; total bilirubin 3.2 mg/dL; albumin 2.4 g/dL; INR 1.8; SCr 0.8 mg/dL. Allergy: none. What is the recommended dose adjustment for this patient?
   Answer: Start with a lower opioid dose and longer interval (e.g., oxycodone 2.5–5 mg per dose with extended dosing interval) and limit total acetaminophen to ≤2 g/day This question examines opioid stewardship in dose adjustment for patients with severe hepatic impairment to prevent toxicity from accumulation. The key patient-specific factor is Child-Pugh C cirrhosis with elevated bilirubin, low albumin, and prolonged INR, indicating reduced hepatic metabolism of opioids and acetaminophen. Starting with a lower oxycodone dose (2.5–5 mg) and extended interval while limiting acetaminophen to ≤2 g/day is best to minimize hepatotoxicity and encephalopathy risk. Using the prescription as written risks overdose due to impaired clearance, avoiding acetaminophen entirely overlooks its utility in multimodal pain control, and increasing the dose ignores tolerance myths in cirrhosis. A clinical pearl is to prefer short-acting opioids at reduced doses in advanced liver disease and monitor for sedation or constipation. Stewardship frameworks should prioritize nonopioid analgesics and regular reassessment in high-risk hepatic patients to enhance safety.
4. A 65-year-old male (88 kg) is admitted for intra-abdominal infection and started empirically on piperacillin/tazobactam 4.5 g IV every 6 hours. Current meds: atorvastatin 40 mg PO nightly and oxycodone 5 mg PO every 6 hours as needed (home). Labs: SCr 1.0 mg/dL; AST/ALT 30/28 units/L; WBC 14.0 $x10^3$/mcL. Culture from abscess grows Enterococcus faecalis susceptible to ampicillin and vancomycin; no Pseudomonas isolated. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
   Answer: De-escalate to ampicillin/sulbactam (or ampicillin if appropriate source control) based on susceptibility and discontinue unnecessary broad-spectrum therapy This question tests antimicrobial de-escalation in intra-abdominal infections once cultures allow narrower therapy to reduce spectrum. The key patient-specific factor is the abscess culture showing Enterococcus faecalis susceptible to ampicillin, without Pseudomonas, supporting targeted beta-lactam use. De-escalating to ampicillin/sulbactam is best as it aligns with susceptibility and minimizes carbapenem exposure. Continuing piperacillin/tazobactam is overly broad, clindamycin lacks enterococcal activity, and adding vancomycin is unnecessary. A stewardship pearl is to de-escalate based on source control and susceptibilities in IAI. Decision frameworks should incorporate rapid diagnostics to optimize therapy duration and spectrum.
5. A 34-year-old male (92 kg) is hospitalized for severe skin and soft tissue infection and is receiving vancomycin IV plus piperacillin/tazobactam IV. Current meds: none. Labs: SCr 0.8 mg/dL; AST/ALT 26/22 units/L; WBC 17.5 $x10^3$/mcL; CRP elevated. Wound culture grows Streptococcus pyogenes; no MRSA isolated; blood cultures negative. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
   Answer: De-escalate to a narrow-spectrum beta-lactam active vs streptococci (e.g., cefazolin or penicillin G) and discontinue broad-spectrum agents This question evaluates antimicrobial de-escalation in skin and soft tissue infections based on culture results to minimize broad-spectrum use. The key patient-specific factor is the wound culture showing Streptococcus pyogenes, with no MRSA or gram-negatives, allowing narrower therapy. De-escalating to cefazolin or penicillin G is best as it targets the pathogen effectively while reducing resistance pressure. Continuing broad therapy is unnecessary, ciprofloxacin lacks optimal streptococcal activity, and adding metronidazole ignores aerobic culture results. A stewardship pearl is to tailor SSTI therapy to gram stain and cultures for shortest durations. Use clinical response and source control in decision frameworks to guide de-escalation in antimicrobial stewardship.
6. A 52-year-old female (78 kg) with chronic knee osteoarthritis has been taking morphine extended-release 30 mg PO twice daily for 2 years and requests an early refill, stating she is taking extra doses due to stress. Current meds: duloxetine 60 mg PO daily and naproxen 500 mg PO twice daily with food. PDMP shows multiple early fills over the past 6 months. Labs: SCr 1.2 mg/dL; AST/ALT 20/18 units/L. Allergy: none. No recent infections; hospitalized 6 months ago for a fall. What is the pharmacist's best recommendation for opioid management?
   Answer: Recommend assessment for opioid use disorder risk and implement a structured plan (e.g., no early refills, consider taper, offer naloxone, and coordinate with prescriber for multimodal pain management) This question examines opioid stewardship in assessing and managing potential opioid use disorder in long-term therapy, including risk mitigation strategies. The key patient-specific factor is the history of multiple early refills and extra doses, suggesting tolerance or misuse in chronic morphine use. Recommending OUD risk assessment, structured plans like no early refills, tapering, and naloxone is best to enhance safety and coordinate care. Increasing the dose escalates risks without addressing underlying issues, switching to meperidine is unsafe for chronic use due to toxicity, and abrupt stopping risks withdrawal. A clinical pearl is to use validated tools like SOAPP-R for OUD risk in chronic pain patients. Stewardship frameworks emphasize multidisciplinary approaches, including behavioral health, for safe opioid deprescribing.
7. A 66-year-old female (60 kg) with rheumatoid arthritis is prescribed codeine/acetaminophen 30 mg/300 mg: take 1 tablet PO every 6 hours as needed for pain after a minor procedure. Current meds: fluoxetine 40 mg PO daily, methotrexate 15 mg PO weekly, and folic acid 1 mg PO daily. Labs: SCr 0.9 mg/dL; AST/ALT 20/18 units/L. Allergy: none. Which action should the pharmacist take to enhance patient safety?
   Answer: Recommend an alternative analgesic because fluoxetine (a CYP2D6 inhibitor) can reduce codeine activation and lead to poor pain control; consider nonopioids or an opioid not dependent on CYP2D6 This question tests opioid stewardship in managing pharmacokinetic drug interactions affecting prodrug activation for pain control. The key patient-specific factor is concurrent fluoxetine, a CYP2D6 inhibitor, which impairs codeine conversion to active morphine. Recommending an alternative analgesic not reliant on CYP2D6 is best to ensure effective pain relief and avoid treatment failure. Dispensing as written risks inefficacy (not enhanced analgesia), doubling the dose could cause toxicity if partially metabolized, and adding rifampin is inappropriate for induction. A clinical pearl is to avoid codeine in CYP2D6 inhibitor users; prefer direct-acting opioids like morphine. Stewardship frameworks should screen for interactions using databases to enhance safety.
8. A 63-year-old male (80 kg) with CKD (estimated creatinine clearance 28 mL/min) is prescribed levofloxacin 750 mg PO daily for 7 days for acute bacterial sinusitis after failing supportive care. Current meds: tizanidine 4 mg PO three times daily as needed and apixaban 5 mg PO twice daily. Labs: SCr 2.0 mg/dL; AST/ALT 19/20 units/L; WBC 9.0 $x10^3$/mcL. Allergy: none. Recent hospitalization: none. What is the recommended dose adjustment for this patient?
   Answer: Adjust levofloxacin for renal impairment (e.g., 750 mg once, then 750 mg every 48 hours or per protocol for creatinine clearance ~20–49 mL/min) This question tests antimicrobial stewardship in dose adjustment for renally cleared drugs like levofloxacin in CKD to prevent toxicity. The key patient-specific factor is the estimated creatinine clearance of 28 mL/min, requiring interval extension to avoid accumulation and QT prolongation. Adjusting to 750 mg once, then every 48 hours is best per guidelines to maintain efficacy while reducing risks. No adjustment risks overdose despite hepatic metabolism claims, increasing the dose exacerbates toxicity, and switching to vancomycin is inappropriate for sinusitis. A stewardship pearl is to use Cockcroft-Gault for dosing adjustments in CKD. Frameworks should include patient education on adherence to adjusted regimens for safety.
9. A 48-year-old female (74 kg) is hospitalized for complicated UTI and started empirically on ceftriaxone 1 g IV every 24 hours. Current meds: oxycodone 5 mg PO every 6 hours as needed and ondansetron 4 mg IV every 6 hours as needed. Labs: SCr 0.9 mg/dL; AST/ALT 22/24 units/L; WBC 12.5 $x10^3$/mcL. Urine culture grows Enterococcus faecium resistant to ampicillin and vancomycin (VRE) and susceptible to linezolid. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
   Answer: Switch to linezolid 600 mg IV/PO every 12 hours (or other VRE-active agent per protocol) and discontinue ceftriaxone This question evaluates antimicrobial de-escalation in complicated UTI when cultures reveal resistance to empiric therapy. The key patient-specific factor is the urine culture showing VRE susceptible to linezolid, rendering ceftriaxone ineffective. Switching to linezolid is best as it provides targeted activity against VRE while discontinuing ineffective agents. Continuing ceftriaxone lacks enterococcal coverage, adding azithromycin offers no synergy, and de-escalating to cephalexin ignores VRE resistance. A stewardship pearl is to reserve linezolid for confirmed VRE to prevent further resistance. Decision frameworks should prioritize susceptibility-guided therapy in UTIs to optimize outcomes.
10. A 64-year-old female (72 kg) is admitted for diabetic foot infection and started empirically on cefepime 2 g IV every 8 hours plus vancomycin IV. Home meds: insulin glargine, gabapentin 300 mg PO three times daily, and hydrocodone/acetaminophen 5/325 mg 1 tablet PO every 6 hours as needed. Labs: SCr 2.0 mg/dL (baseline 1.9), estimated creatinine clearance 25 mL/min; AST/ALT 30/26 units/L; WBC 13.2 $x10^3$/mcL. Allergy: none. Wound culture pending. What is the recommended dose adjustment for this patient?
    Answer: Reduce cefepime dose/frequency for creatinine clearance 25 mL/min (e.g., 2 g IV every 24 hours per protocol) to reduce neurotoxicity risk This question assesses antimicrobial stewardship in dose adjustment for beta-lactams in renal impairment to prevent toxicity during diabetic foot infection treatment. The key patient-specific factor is the reduced creatinine clearance (25 mL/min) in a patient on cefepime, increasing seizure risk from accumulation. Reducing cefepime to 2 g IV every 24 hours is best to maintain efficacy while minimizing neurotoxicity in CKD. Continuing or increasing the dose risks overdose, and switching to clindamycin ignores pending cultures and lacks broad empiric coverage. A stewardship pearl is to adjust renally cleared antibiotics like cefepime based on estimated creatinine clearance using protocols. Always consider patient comorbidities like diabetes when evaluating toxicity risks in antimicrobial dosing frameworks.
11. A 70-year-old female (62 kg) on chronic opioid therapy for neuropathic pain takes hydromorphone immediate-release 4 mg PO every 6 hours scheduled (total 16 mg/day) and gabapentin 600 mg PO three times daily. Current meds also include zolpidem 10 mg PO at bedtime as needed. She reports two recent near-falls and confusion. Labs: SCr 1.1 mg/dL; AST/ALT 23/21 units/L. Allergy: none. No recent infections or hospitalizations. What action should the pharmacist take to enhance patient safety?
    Answer: Recommend reassessing sedating co-medications (e.g., avoid zolpidem), consider opioid dose reduction/taper and fall-risk mitigation, and offer naloxone due to overdose risk This question evaluates opioid stewardship principles focused on minimizing risks in elderly patients, including sedation, falls, and overdose through deprescribing and harm reduction strategies. The key patient-specific factors are the patient's age (70 years), reports of near-falls and confusion, and concurrent use of sedating medications like zolpidem alongside chronic opioids and gabapentin. Reassessing sedating co-medications, considering opioid dose reduction or taper, implementing fall-risk mitigation, and offering naloxone is the best action as it addresses polypharmacy-induced risks, promotes safety, and aligns with guidelines for high-risk opioid users. Adding diphenhydramine is incorrect as it would exacerbate sedation and fall risk without addressing underlying issues, while increasing hydromorphone would likely worsen confusion and sedation rather than improve pain control. Switching to meperidine is suboptimal due to its neurotoxic metabolites, which pose higher risks of delirium in older adults. A transferable clinical pearl is to use tools like the Beers Criteria to identify potentially inappropriate medications in the elderly and prioritize non-opioid alternatives. In opioid stewardship, a decision framework should include regular risk assessments using tools like the Opioid Risk Tool and ensuring naloxone access for all patients on chronic opioids.
12. A 59-year-old male (86 kg) is receiving clindamycin 600 mg IV every 8 hours plus ceftriaxone 2 g IV every 24 hours for aspiration pneumonia. Current meds: pantoprazole 40 mg PO daily and tramadol 50 mg PO every 6 hours as needed. Labs: SCr 1.0 mg/dL; AST/ALT 28/26 units/L; WBC 11.5 $x10^3$/mcL. Allergy: none. He develops watery diarrhea on day 4 of therapy and has abdominal cramping; temperature 38.1°C. Which monitoring parameter is most critical for this patient?
    Answer: Stool testing for Clostridioides difficile toxin/NAAT and monitoring frequency/severity of diarrhea This question assesses monitoring for antibiotic-associated diarrhea, specifically Clostridioides difficile infection, in patients on high-risk antibiotics. The key patient-specific factor is the development of watery diarrhea and cramping on day 4 of clindamycin, a known CDI risk factor. Stool testing for C. difficile and monitoring diarrhea severity is critical to diagnose and manage potential CDI promptly. Serum calcium is irrelevant, troponin lacks cardiac indication, and urine ketones are unrelated. A stewardship pearl is to minimize clindamycin use due to high CDI association and consider probiotics in select cases. Frameworks should include early testing and isolation protocols for suspected CDI in stewardship practice.
13. A 55-year-old female (83 kg) with CKD (estimated creatinine clearance 18 mL/min, not on dialysis) is prescribed acyclovir 800 mg PO five times daily for herpes zoster. Current meds: hydrochlorothiazide 25 mg PO daily and oxycodone 5 mg PO every 8 hours as needed. Labs: SCr 3.1 mg/dL; AST/ALT 18/17 units/L; WBC 7.5 $x10^3$/mcL. Allergy: none. What is the recommended dose adjustment for this patient?
    Answer: Adjust acyclovir dosing interval for renal impairment (e.g., reduce frequency such as 800 mg PO every 12 hours per protocol for creatinine clearance ~10–25 mL/min) This question assesses antimicrobial stewardship in dose adjustment for acyclovir in renal impairment to prevent neurotoxicity. The key patient-specific factor is the low creatinine clearance (18 mL/min) in a non-dialysis CKD patient, necessitating reduced frequency. Adjusting to 800 mg PO every 12 hours is best to avoid accumulation while treating herpes zoster effectively. No adjustment risks seizures, increasing the dose exacerbates toxicity, and switching to nitrofurantoin is inappropriate for zoster. A stewardship pearl is to adjust acyclovir based on ideal body weight and CrCl for safety. Frameworks should include monitoring for CNS effects in renally impaired patients on antivirals.
14. A 69-year-old female (64 kg) is treated for hospital-acquired pneumonia with vancomycin IV plus cefepime IV. Home meds: hydrochlorothiazide 25 mg PO daily. Labs: SCr 1.4 mg/dL (baseline 0.9), estimated creatinine clearance 35 mL/min; AST/ALT 23/20 units/L; WBC 15.0 $x10^3$/mcL. Sputum culture grows methicillin-susceptible Staphylococcus aureus (MSSA) susceptible to oxacillin/cefazolin; MRSA nasal PCR is negative. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
    Answer: De-escalate to cefazolin (or nafcillin/oxacillin) and discontinue vancomycin and cefepime if no other indication This question tests antimicrobial de-escalation for hospital-acquired pneumonia when cultures confirm a narrower-spectrum option is appropriate. The key patient-specific factor is the sputum culture identifying MSSA susceptible to cefazolin, with negative MRSA PCR supporting vancomycin discontinuation. De-escalating to cefazolin is best as beta-lactams are preferred for MSSA due to superior outcomes over vancomycin. Continuing vancomycin exposes the patient to unnecessary toxicity, daptomycin is suboptimal for pneumonia, and adding aztreonam lacks gram-positive relevance. A stewardship pearl is to prefer anti-staphylococcal penicillins or cefazolin for MSSA infections to improve efficacy and reduce resistance. Use MRSA screening to guide empiric therapy de-escalation in pneumonia stewardship protocols.
15. A 62-year-old male (90 kg) is being treated for MRSA bacteremia with vancomycin IV (pharmacy-managed dosing) plus piperacillin/tazobactam 4.5 g IV every 6 hours started empirically. Home meds: metformin 1000 mg PO twice daily and ibuprofen 400 mg PO three times daily as needed. Labs: SCr increased from 0.9 to 1.6 mg/dL over 3 days; AST/ALT 25/21 units/L; WBC 12.0 $x10^3$/mcL. Blood cultures now identify MRSA; no gram-negative organisms; repeat cultures pending. Allergy: none. What action should the pharmacist take to enhance patient safety?
    Answer: Recommend discontinuing piperacillin/tazobactam if no ongoing gram-negative indication and optimize vancomycin exposure using AUC-guided monitoring to reduce nephrotoxicity This question tests antimicrobial stewardship in optimizing vancomycin therapy and de-escalating unnecessary antibiotics to prevent nephrotoxicity in MRSA bacteremia. The key patient-specific factor is the rising serum creatinine (from 0.9 to 1.6 mg/dL) during concomitant vancomycin and piperacillin/tazobactam, with cultures confirming MRSA but no gram-negatives. Recommending discontinuation of piperacillin/tazobactam and AUC-guided vancomycin monitoring is best to reduce nephrotoxicity risk while ensuring adequate MRSA coverage. Adding gentamicin increases toxicity without synergy benefit here, increasing vancomycin to high troughs ignores renal changes, and adding ketorolac risks further kidney injury. A stewardship pearl is to avoid vancomycin-piperacillin/tazobactam combinations when possible due to heightened AKI risk. Use AUC monitoring over troughs for vancomycin to balance efficacy and safety in stewardship practice.
16. A 27-year-old female (63 kg) presents to the pharmacy with a new prescription for oxycodone 5 mg tablets: take 1 tablet PO every 6 hours as needed for pain for 3 days after minor surgery. Current meds: none. Labs: SCr 0.8 mg/dL; AST/ALT 18/16 units/L. Allergy: none. No recent infections or hospitalizations. Which counseling point is most important for this opioid prescription?
    Answer: Use nonopioid options first (acetaminophen/ibuprofen if appropriate), avoid driving or operating machinery until you know how it affects you, and store/lock up and dispose of unused tablets properly This question evaluates opioid stewardship counseling for short-term use post-surgery to promote safe administration and prevent misuse. The key patient-specific factor is the opioid-naive status in a young patient, increasing risks of sedation and dependence if not used judiciously. Counseling on nonopioid priority, avoiding machinery, and proper storage/disposal is most important to minimize harm and diversion. Taking extra for sleepiness risks overdose, crushing alters release, and fixed scheduling promotes unnecessary use. A clinical pearl is to limit opioid quantities to expected needs and encourage multimodal pain relief. Stewardship practices should emphasize education on risks and alternatives to reduce opioid-related harms.
17. A 67-year-old male (82 kg) is hospitalized for community-acquired pneumonia and was started empirically on piperacillin/tazobactam 3.375 g IV every 6 hours plus vancomycin 1.25 g IV every 12 hours 48 hours ago. Current medications also include lisinopril 10 mg PO daily and acetaminophen 650 mg PO every 6 hours as needed. Labs: SCr 1.0 mg/dL; AST/ALT 22/19 units/L; WBC 9.8 $x10^3$/mcL; procalcitonin decreased from 1.8 to 0.4 ng/mL. Sputum culture grows Streptococcus pneumoniae susceptible to penicillin and ceftriaxone; MRSA nasal PCR is negative; blood cultures show no growth. Allergy: rash to sulfonamides. Which intervention is most appropriate for this patient's antimicrobial therapy?
    Answer: De-escalate to ceftriaxone 1 g IV every 24 hours (or equivalent targeted beta-lactam) and discontinue vancomycin and piperacillin/tazobactam This question tests the principle of antimicrobial de-escalation in empirical therapy for community-acquired pneumonia once culture results guide targeted treatment. The key patient-specific factor is the sputum culture revealing Streptococcus pneumoniae susceptible to penicillin and ceftriaxone, combined with negative MRSA nasal PCR and improving procalcitonin. De-escalating to ceftriaxone 1 g IV every 24 hours is the best choice as it provides effective, narrow-spectrum coverage against the identified pathogen while minimizing unnecessary broad-spectrum antibiotic exposure. Continuing piperacillin/tazobactam plus vancomycin is suboptimal as it promotes resistance without added benefit given the susceptibility profile, and switching to trimethoprim/sulfamethoxazole is inappropriate due to the sulfa allergy and lack of first-line indication for pneumococcal pneumonia. Adding azithromycin is unnecessary as there is no evidence of atypical pathogens, and the regimen already covers typical bacteria adequately. A key stewardship pearl is to de-escalate antibiotics based on culture results and clinical improvement to reduce selective pressure for resistance. Always reassess the need for MRSA coverage using tools like nasal PCR to guide vancomycin discontinuation.
18. A 76-year-old male (68 kg) with chronic kidney disease is admitted for pyelonephritis and is receiving gentamicin 5 mg/kg IV every 24 hours plus ceftriaxone 1 g IV every 24 hours. Home meds: furosemide 40 mg PO daily and amlodipine 5 mg PO daily. Labs: SCr 2.2 mg/dL (baseline 1.8 mg/dL), estimated creatinine clearance 25 mL/min; AST/ALT 20/18 units/L; WBC 14.5 $x10^3$/mcL. Allergy: anaphylaxis to penicillin. Recent hospitalization 1 month ago for UTI. Which monitoring parameter is most critical for this patient?
    Answer: Gentamicin serum concentrations (peak/trough or AUC-based monitoring) and serial serum creatinine This question assesses antimicrobial stewardship monitoring for aminoglycoside therapy in patients with renal impairment during treatment for pyelonephritis. The key patient-specific factor is the baseline chronic kidney disease with reduced creatinine clearance (25 mL/min) and recent gentamicin use, increasing nephrotoxicity risk. Monitoring gentamicin serum concentrations (peak/trough or AUC-based) and serial serum creatinine is critical to ensure therapeutic levels while preventing further renal damage. Weekly hemoglobin A1c is irrelevant without diabetes, daily INR is unnecessary without anticoagulants, and serum uric acid lacks relevance to gentamicin toxicity. A stewardship pearl is to use extended-interval dosing and pharmacokinetic monitoring for aminoglycosides in renal impairment to optimize efficacy and minimize ototoxicity/nephrotoxicity. Always consider patient-specific factors like prior exposure and concurrent nephrotoxins when selecting monitoring parameters in antimicrobial therapy.
19. A 73-year-old male (75 kg) is receiving IV antibiotics for presumed sepsis: meropenem 1 g IV every 8 hours plus vancomycin IV. Current meds: warfarin 5 mg PO daily and metoprolol succinate 50 mg PO daily. Labs: SCr 1.1 mg/dL; AST/ALT 27/29 units/L; WBC 16.0 $x10^3$/mcL; lactate improved. Cultures return: urine culture grows ESBL-negative E. coli susceptible to ceftriaxone; blood cultures negative at 48 hours. Allergy: none. Which intervention is most appropriate for this patient's antimicrobial therapy?
    Answer: De-escalate to ceftriaxone 1 g IV every 24 hours (or appropriate oral step-down when stable) and discontinue meropenem and vancomycin This question tests antimicrobial de-escalation in sepsis management once cultures identify a susceptible pathogen to reduce broad-spectrum exposure. The key patient-specific factor is the urine culture showing ESBL-negative E. coli susceptible to ceftriaxone, with negative blood cultures indicating targeted therapy is sufficient. De-escalating to ceftriaxone 1 g IV every 24 hours is best as it effectively treats the pathogen while sparing carbapenem use and vancomycin. Continuing meropenem unnecessarily promotes resistance, switching to linezolid lacks gram-negative activity, and adding metronidazole is irrelevant without anaerobes. A stewardship pearl is to de-escalate based on susceptibility and source control in sepsis to preserve last-line antibiotics. Use rapid diagnostics and clinical response to guide duration and spectrum in antimicrobial frameworks.
20. A 71-year-old female (58 kg) with COPD is treated for suspected ventilator-associated pneumonia and is receiving vancomycin IV plus tobramycin IV plus cefepime IV. Home meds: prednisone 10 mg PO daily and albuterol inhaler. Labs: SCr 1.3 mg/dL (baseline 1.0); AST/ALT 24/22 units/L; WBC 18.0 $x10^3$/mcL. Allergy: none. Recent hospitalization 2 weeks ago with prior aminoglycoside exposure. Which monitoring parameter is most critical for this patient?
    Answer: Audiology assessment and aminoglycoside serum concentrations with serial renal function monitoring This question assesses monitoring for aminoglycoside toxicities in high-risk patients during treatment for ventilator-associated pneumonia. The key patient-specific factor is the elderly patient with prior aminoglycoside exposure, reduced renal function, and COPD, elevating ototoxicity and nephrotoxicity risks. Audiology assessment, tobramycin levels, and serial renal monitoring are critical to prevent irreversible hearing loss and AKI. Serum magnesium alone overlooks broader toxicities, CK is irrelevant to cefepime, and amylase/lipase lack association. A stewardship pearl is to limit aminoglycoside duration and use baseline/periodic audiology in prolonged therapy. Frameworks should risk-stratify patients for enhanced monitoring in antimicrobial stewardship.

Start this quiz